Nonsteroidal anti-inflammatory drugs (NSAID) are among the most widely used drugs. NSAIDs are considered safe enough to make these available as over-the-counter drugs in many countries. However, they are far from being adverse events-free. Nearly 25 % of the population have experienced NSAID-related adverse events that require medical care. Major NSAID-related adverse events affect the gastrointestinal, renal, or cardiovascular and include hypersensitivity reactions that, on occasions, can be life-threatening.
To provide guidance on NSAIDs dosing and/or use based on pharmacogenomics tests, a group of international experts elaborated a Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs, since CYP2C9 is a crucial enzyme in the metabolism of several NSAIDs. During the elaboration process of this guideline, it became evident the limited information available and the need of gaining more ground on the influence of polymorphic metabolism in pharmacokinetics, drug response and the risk of developing adverse events for many widely used NSAIDs.
This Research Topic aims to gather a collection of papers that hopefully will fill relevant gaps in this field. Besides CYP2C9, NSAIDs are metabolized by several polymorphic drug-metabolizing enzymes including both, Phase I and Phase II enzymes. We encourage the submission of well-powered studies on the effect of functional polymorphisms of drug-metabolizing enzymes in the pharmacokinetics, efficacy, adverse drug events, or drug-drug interactions related to NSAIDs.
Submission of case reports and short case series are encouraged too, as long as data are provided in sufficient detail to include these cases in meta-analyses. Information provided in supplemental tables should include, for each case, covariables that might influence the effects of genetic variations (such as gender, age or concomitant diseases), type of NSAID, dose, duration of the treatment, pharmacokinetic or other outcome parameters, genes, and specific variations interrogated.
Hopefully, this novel information will help to actualize, and to developing novel clinical practice guidelines and, ultimately, will promote safer use of NSAIDs.
Nonsteroidal anti-inflammatory drugs (NSAID) are among the most widely used drugs. NSAIDs are considered safe enough to make these available as over-the-counter drugs in many countries. However, they are far from being adverse events-free. Nearly 25 % of the population have experienced NSAID-related adverse events that require medical care. Major NSAID-related adverse events affect the gastrointestinal, renal, or cardiovascular and include hypersensitivity reactions that, on occasions, can be life-threatening.
To provide guidance on NSAIDs dosing and/or use based on pharmacogenomics tests, a group of international experts elaborated a Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs, since CYP2C9 is a crucial enzyme in the metabolism of several NSAIDs. During the elaboration process of this guideline, it became evident the limited information available and the need of gaining more ground on the influence of polymorphic metabolism in pharmacokinetics, drug response and the risk of developing adverse events for many widely used NSAIDs.
This Research Topic aims to gather a collection of papers that hopefully will fill relevant gaps in this field. Besides CYP2C9, NSAIDs are metabolized by several polymorphic drug-metabolizing enzymes including both, Phase I and Phase II enzymes. We encourage the submission of well-powered studies on the effect of functional polymorphisms of drug-metabolizing enzymes in the pharmacokinetics, efficacy, adverse drug events, or drug-drug interactions related to NSAIDs.
Submission of case reports and short case series are encouraged too, as long as data are provided in sufficient detail to include these cases in meta-analyses. Information provided in supplemental tables should include, for each case, covariables that might influence the effects of genetic variations (such as gender, age or concomitant diseases), type of NSAID, dose, duration of the treatment, pharmacokinetic or other outcome parameters, genes, and specific variations interrogated.
Hopefully, this novel information will help to actualize, and to developing novel clinical practice guidelines and, ultimately, will promote safer use of NSAIDs.